Tocagen is planning a Phase 1 trial to evaluate Toca 511 & Toca FC in patients with recurrent high-grade non-muscle invasive bladder cancer (NMIBC). Results from our preclinical studies and clinical trial evaluating our cancer-selective gene therapy in solid tumor cancers encouraged us to explore the potential therapeutic benefit of Toca 511 & Toca FC in this indication. Trial activation is expected in 2019.
The trial will evaluate the safety and tolerability of the regimen and the presence of Toca 511 virus in tumors of patients with recurrent disease who are planning to have surgery to remove the tumor. Immunologic activity will also be studied. More information about the trial is available here.
Participation in a clinical trial is one possible option for people who have cancer. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.